> ## Content Index
> Fetch the complete content index at: https://www.theamericanquorum.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Moderna Reports 100% Observed Efficacy in TeenCOVE Trial and Plans FDA Filing for Ages 12 to 17
- URL: https://www.theamericanquorum.com/moderna-teencove-100-percent-observed-efficacy-adolescents/
- Published: 2021-05-30T03:59:00.000Z
- Updated: 2021-05-30T03:59:00.000Z
- Description: Moderna says its TeenCOVE trial found no COVID-19 cases after two doses among vaccinated adolescents and plans to seek U.S. authorization for ages 12 to 17 in early June.
- Author: Kenneth R. Deans Jr.
- Tags: Healthcare, #Import 2026-08-30 04:52

Moderna said this week that its COVID-19 vaccine produced no cases of symptomatic disease among fully vaccinated adolescents in its Phase 2/3 TeenCOVE trial, giving the United States a potential second vaccine option for people ages 12 to 17 as the national campaign moves deeper into younger populations.

The company reported that the study enrolled more than 3,700 adolescents and met its primary immunogenicity endpoint by showing an immune response comparable to that seen in vaccinated young adults. Under the primary case definition, Moderna said there were no COVID-19 cases in participants who had received both doses, corresponding to [100% observed efficacy](https://www.pharmiweb.com/press-release/2021-05-26/moderna-announces-teencove-study-of-its-covid-19-vaccine-in-adolescents-meets-primary-endpoint-and-plans-to-submit-data-to-regulators-in-early-june?ref=theamericanquorum.com) in the analyzed period. The company said it plans to submit the data to the Food and Drug Administration and other regulators in early June.

The findings are preliminary and have not yet gone through the full regulatory review that would be required before the vaccine can be used in adolescents under an expanded emergency authorization. But they strengthen the evidence that the two-dose mRNA vaccine platform can generate strong protection in teenagers as well as adults.

## TeenCOVE was designed to bridge adolescent responses to adults

The TeenCOVE study is registered with the federal [ClinicalTrials.gov database](https://clinicaltrials.gov/study/NCT04649151?ref=theamericanquorum.com) as a randomized, observer-blind, placebo-controlled Phase 2/3 trial evaluating safety, reactogenicity and effectiveness of mRNA-1273 in healthy adolescents ages 12 to under 18.

Participants received two 100-microgram doses of Moderna’s vaccine or placebo. The primary immunogenicity analysis compared neutralizing antibody responses in adolescents with responses observed in the company’s adult vaccine program. Moderna said that endpoint was met, meaning the adolescent immune response was not inferior to the adult comparator group.

The company also evaluated clinical disease. Using the primary definition, no cases occurred among fully vaccinated adolescents after the second dose, compared with cases in the placebo group. Using a broader CDC case definition that captures milder disease, Moderna reported [93% efficacy](https://www.techtarget.com/pharmalifesciences/news/366607208/Modernas-mRNA-COVID-19-Vaccine-100-Effective-in-Adolescents?ref=theamericanquorum.com) beginning 14 days after the first dose.

Those estimates are encouraging, but their precision is limited by the relatively small number of COVID-19 cases in the trial. Regulators will examine the complete dataset, including adverse events, follow-up time and manufacturing information, rather than relying on the headline efficacy percentage alone.

## Pfizer has already opened the adolescent market

Moderna is following Pfizer-BioNTech, whose vaccine became the first COVID-19 vaccine authorized in the United States for people ages 12 to 15 earlier this month. Pfizer said its own 2,260-participant adolescent trial also produced [100% observed efficacy](https://www.pfizer.com/news/press-release/press-release-detail/pfizer-and-biontech-receive-first-us-authorization?ref=theamericanquorum.com) against symptomatic COVID-19 in the analyzed trial period.

CDC subsequently recommended Pfizer-BioNTech vaccination for adolescents and summarized the evidence in an [MMWR report](https://www.cdc.gov/mmwr/volumes/70/wr/mm7020e1.htm?ref=theamericanquorum.com). The agency found high certainty for prevention of symptomatic disease while noting that the trial was not large enough to measure uncommon serious adverse events with precision.

The FDA’s [COVID-19 regulatory record](https://www.fda.gov/emergency-preparedness-and-response/public-health-preparedness-and-response/coronavirus-disease-2019-covid-19?ref=theamericanquorum.com) lists the May 10 expansion of Pfizer’s emergency authorization to adolescents 12 through 15 and shows that the agency is preparing for broader pediatric vaccine questions. A June 10 advisory committee meeting is scheduled to discuss the evidence needed for authorization or licensure of COVID-19 vaccines in pediatric populations.

That regulatory sequence matters for Moderna. Pfizer’s authorization does not guarantee that another mRNA vaccine will receive the same decision. Moderna will have to show that its own benefit-risk profile is favorable for adolescents using its dose, manufacturing process and trial data.

## Safety will receive particular attention

Moderna said the vaccine was generally well tolerated in TeenCOVE and that the safety profile was consistent with what had been seen in adults. Common reactions included injection-site pain, headache, fatigue, muscle aches and chills. No significant safety concerns were identified in the company’s initial analysis.

Adolescent vaccine decisions nevertheless carry a different risk-benefit calculation than decisions for older adults. Teenagers face a substantially lower risk of hospitalization and death from COVID-19 than elderly people, although severe disease, hospitalization and multisystem inflammatory syndrome can occur. That makes even uncommon adverse events especially important to characterize.

The CDC’s [evidence review](https://www.cdc.gov/acip/grade/covid-19-pfizer-biontech-vaccine-12-15-years.html?ref=theamericanquorum.com) for Pfizer’s adolescent vaccine illustrates the framework regulators and public-health officials are using: weigh prevention of symptomatic disease and broader transmission benefits against reactogenicity, serious adverse events and uncertainties created by limited follow-up.

Both Moderna and Pfizer plan continued monitoring of adolescent participants. As millions of younger people become vaccinated, national safety-surveillance systems will also accumulate evidence capable of detecting events too rare to emerge in trials involving only a few thousand participants.

## A second vaccine could expand access and flexibility

If the FDA authorizes Moderna for adolescents, clinicians and vaccination programs would gain another supply option. Pfizer’s vaccine currently fills the entire authorized U.S. adolescent market. Competition between two products could simplify logistics for providers that already stock Moderna for adults and give states additional flexibility as mass vaccination sites shift toward pharmacies, primary-care offices and community programs.

The timing also matters for schools. Families are making decisions about summer activities and the next academic year, while colleges and some institutions are announcing vaccination requirements. A second adolescent vaccine could broaden availability before the fall.

The larger challenge is now demand rather than supply. Adult first-dose vaccinations have slowed from their April peak even as vaccine availability has become widespread. Expanding eligibility can temporarily increase the pool of people seeking shots, but sustained progress will depend on confidence among parents and adolescents as well as convenient access.

Moderna’s announcement therefore represents both a scientific milestone and a test of the next phase of the vaccination campaign. The company has shown that its vaccine can generate strong immune responses in teenagers and, in the trial period analyzed so far, prevent symptomatic cases. The next step belongs to regulators, who must determine whether the evidence is sufficient to extend emergency use to millions more Americans.